Literature DB >> 3541170

Serum IgA to enterobacteria in ankylosing spondylitis.

C G van Bohemen, A J Nabbe, H S Goei The, E S Mazurkiewicz, S van der Linden, H C Zanen.   

Abstract

The aetiology of ankylosing spondylitis (AS) may involve certain enterobacteria. It is therefore interesting that serum polymeric IgA, a precursor of secretory IgA, was statistically elevated in active AS (n = 35) and that levels were comparable to those found in yersiniosis (n = 12); this might indicate antigenic stimulation by bacteria which are present in the intestines of AS patients. However, specific serum IgA to the incriminated enterobacteria Klebsiella, Shigella and Yersinia, as determined by ELISA, was not raised in the above AS patients. Nor were these titres raised in patients with idiopathic reactive arthritis (n = 21). In contrast, yersiniosis (n = 12) and shigellosis (n = 96) patients displayed marked increases in specific serum IgA titres to the respective infectants. It is proposed that AS may involve a set of enterobacteria rather than a few suspected species. Thus, despite the lack of raised group averages, screening of individual patients for specific IgA to several indicated bacteria might disclose whether or not raised serum IgA is related to enterobacterial activity. Apart from this, the above supports other reports indicating that serum IgA may be a useful parameter to assist in monitoring of disease activity in AS. Finally, it is suggested that study of a homogeneous group of reactive arthritis patients might facilitate aetiological research of seronegative arthropathies such as AS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3541170     DOI: 10.3109/03009748609092598

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  2 in total

1.  Coincident seronegative spondarthritis: a case report.

Authors:  C A Speed; I Haslock
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

2.  Bacterial antibodies in ankylosing spondylitis.

Authors:  O Mäki-Ikola; K Lehtinen; K Granfors; R Vainionpää; P Toivanen
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.